10. Stock-Based Compensation

Equity Incentive Plans

In September 2012, the Company adopted the 2012 Equity Incentive Plan, as amended (the "Plan"), which provides designated employees of the Company and its affiliates, certain consultants and advisors who perform services for the Company and its affiliates, and nonemployee members of the Board of Directors of the Company and its affiliates with the opportunity to receive grants of incentive stock options, nonqualified stock options and stock awards. As of December 31, 2017, the aggregate number of shares of common stock of the Company that may be issued under the Plan was 61,483. As of December 31, 2017, no shares were available for future grant under the Plan.

On January 20, 2017, the Company's stockholders approved the amended and restated 2012 Equity Incentive Plan (the "2012 Plan"), which amended and restated the Plan and was effective in connection with the completion of the Company's merger with Macrocure. A total of 1,387,204 shares of common stock were reserved for issuance under the 2012 Plan. As of December 31, 2017, no shares remained available for future grant under the 2012 Plan.

On January 20, 2017, the Company's stockholders approved the 2016 Equity Incentive Plan (the "2016 Plan"), which was effective in connection with the completion of the Company's merger with Macrocure. The number of shares of common stock issuable pursuant to outstanding awards granted under the 2016 Plan may not exceed the number that is equal to the sum of (i) 854,321 shares of common stock plus (ii) the number of shares of common stock (not to exceed 103,023 shares) subject to out-of-the-money options issued by Macrocure prior to the closing of the merger and assumed by the Company pursuant to the merger agreement upon consummation of the merger that expire unexercised. Beginning on January 1, 2018, the number of shares of common stock authorized for issuance pursuant to the 2016 Plan will be increased each January 1 by an amount equal to four percent (4%) of the Company's outstanding common stock as of the end of the immediately preceding calendar year or such other amount as determined by the compensation committee of the Company's Board of Directors.

In connection with the merger with Macrocure in January 2017, the Company assumed the Macrocure 2013 Share Incentive Plan (the "2013 Plan"), the Macrocure 2008 Stock Option Plan (the "2008 Plan") and all stock options outstanding under each of the 2013 Plan and the 2008 Plan immediately prior to the consummation of the merger. By virtue of the terms of the Merger Agreement and the 2013 Plan or the 2008 Plan, as applicable, each stock option outstanding immediately prior to the consummation of the merger was automatically converted into a stock option exercisable for a number of shares of the Company's common stock calculated based on the exchange ratio and the exercise price per share of such outstanding stock option.

The Company could also make awards of restricted stock under the 2016 Plan. Restricted stock may be issued under the Equity Plan for such consideration, in cash, other property or services, or any combination thereof, as is determined by the Board of Directors. During the restriction period applicable to the shares of restricted stock, such shares shall be subject to limitations on transferability, subject to forfeiture or repurchase by the Company and/or subject to other terms and conditions. Upon lapse of such restrictions, the stock certificates representing shares of common stock shall be delivered to the grantee.

A summary of activity under the Plan is as follows:

	Options			Weighted Average Exercise Price Per Share		Weighted Average Remaining Life in Years		Aggregate Intrinsic Value
Outstanding at December 31, 2015		59,274		$	4.95		7.90
Forfeited		(6,046	)	$	5.14

Outstanding at December 31, 2016		53,228		$	4.93		7.00	$	213

Granted		2,220,858		$	12.51
Exercised		(3,506	)	$	5.55
Forfeited		(12,959	)	$	5.78

Outstanding at December 31, 2017		2,257,621		$	12.38		8.66	$	68

Options exercisable at December 31, 2017		716,316		$	19.62		7.35	$	65
Options vested and expected to vest at December 31, 2017		2,257,621		$	12.38		8.66	$	68

During the years ended December 31, 2017 and 2016 the Company recognized $5,600 and $45 respectively, of stock-based compensation expense.

The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis:

	Year Ended December 31,
	2017
Expected volatility		68.7	%
Weighted average risk-free interest rate		2.1	%
Expected dividend yield		0.0	%
Expected term (in years)		6.6

The Company did not grant any stock options during 2016.

Stock options generally vest 25% on the one-year anniversary of the date of grant and quarterly thereafter during the subsequent three years. The options expire ten years from the grant date. As of December 31, 2017, there was approximately $6,834 of unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over a remaining weighted-average period of approximately 2.57 years.

Stock-based compensation expense was classified in the consolidated statements of operations as follows:

	Year Ended December 31,
	2017		2016
Research and development	$	1,834	$	35
General and administrative		3,766		10

Total	$	5,600	$	45